0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-1

B7-1

B7-1 Molecule Information

Name:Cluster of differentiation 80
Target Synonym:Activation B7-1 antigen,LAB7,T-lymphocyte activation antigen CD80,CD80 Molecule,CD80 Antigen (CD28 Antigen Ligand 1, B7-1 Antigen),B-Lymphocyte Activation Antigen B7,CTLA-4 Counter-Receptor B7.1,CD28LG1,BB1,Costimulatory Molecule Variant IgV-CD80,Costimul
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

B7-1 Protein Product ListCompare or Buy

B7-1 Part of Bioactivity data

B71-H52A4-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Human B7-1, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B71-H52A4) can bind to 293 cell overexpressing human CTLA-4. The concentration of Human B7-1 is 1 μg/mL (Routinely tested).

B71-H52A4-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of Human B7-1, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B71-H52A4) to 293 overexpressing CTLA-4 was inhibited by increasing concentration of neutralizing Anti-human CTLA-4 antibody. The concentration of Human B7-1 is 1 μg /mL. The IC50 is 5.5 μg/mL (Routinely tested).

B71-H52A4-SPR
Human_FcRn_Heterodimer_Protein_SPR

Immobilized Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (HPLC-verified) (Cat. No. CD8-H525a) on CM5 Chip can bind Human B7-1, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B71-H52A4) with an affinity constant of 2.72 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

B71-H5228-SPR
Human_FcRn_Heterodimer_Protein_SPR

Immobilized Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (HPLC-verified) (Cat. No. CD8-H525a) on CM5 Chip can bind Human B7-1, His Tag (Cat. No. B71-H5228) with an affinity constant of 5.29 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

B7-1 Customer Reviews

B7-1 Molecule Synonym Name

CD80,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7

B7-1 Molecule Background

B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-?B-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

B7-1 Related Molecule

B7-1 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Belatacept LEA29Y; LEA-029; BMS-224818; L104EA29YIg Approved Bristol-Myers Squibb Company Nulojix EU Rejection of renal transplantation s:32:"Bristol-Myers Squibb Pharma Eeig"; 2011-06-15 Rejection of renal transplantation; Rejection of organ transplantation Details
Abatacept BMS-188667; BMS-188667SC; ONO-4164SC; ONO-4164 Approved Bristol-Myers Squibb Company Orencia Mainland China Arthritis, Rheumatoid s:28:"Bristol-Myers Squibb Company"; 2005-12-23 Multiple Sclerosis; Crohn Disease; Nephrotic Syndrome; Muscular Diseases; Colitis, Ulcerative; Arthritis, Psoriatic; Glomerulosclerosis, Focal Segmental; Lupus Erythematosus, Systemic; Psoriasis; Polymyositis; Nephrosis, Lipoid; Lupus Nephritis; Arthritis, Juvenile; Sjogren's Syndrome; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Dermatomyositis; Giant Cell Arteritis Details

B7-1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase 1 Clinical Hunan Zhaotai Yongren Biotech Carcinoma, Non-Small-Cell Lung Details
rVV-740CTA vaccine (University Hospital Basel) rVV-740CTA Phase 1 Clinical University Hospital Basel Breast Neoplasms Details
Belatacept biosimilar (Alphamab) KN-019 Phase 2 Clinical Suzhou Alphamab Co Ltd Rejection of renal transplantation; Arthritis, Rheumatoid; Autoimmune Diseases Details

This web search service is supported by Google Inc.

totop